This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/5/2026
Good morning and welcome to RGO's Pharmaceutical Third Quarter 2026 conference call. At this time, all participants are in the listen-only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at RGO's request. I would now like to turn the call over to Morgan Sanford, Vice President of Investor Relations at RGO. Thank you. Please go ahead.
Thank you, Operator. Good morning, everyone. Thank you for joining us to discuss Agios Pharmaceuticals' third quarter 2026 financial results and business highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com. Next slide, please. Please note we'll be making certain forward-looking statements today. Actual events and results could differ materially from those expressed or implied by any forward-looking statements because of various risks and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. On the next slide, we have the agenda for today's call. With me today from Agios are Brian Goff, Chief Executive Officer, Cecilia Jones, Chief Financial Officer, Sveta Milanova, Chief Commercial Officer, and Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development. Following prepared remarks, we will open the call for questions. With that, I am pleased to turn the call over to Brian.
Thanks, Morgan. Good morning, everyone, and thank you for joining us. Next slide, please. The third quarter delivered record product revenue for Agios and is a clear demonstration of our commercial execution. We delivered $55.4 million in total net revenue more than four times the third quarter of last year. U.S. net revenue was $48.7 million, driven by the continued strong U.S. launch of Akvesby and Thalassemia. To put that in perspective, in a single quarter, we generated more total revenue than we did in all of 2025. This performance reflects what we are building, a focused rare hematology company with a scalable commercial foundation. Thalassemia is the first launched to leverage that foundation. Sickle cell disease, our largest opportunity, is next. And I'll speak to the status of our mid-pivot SNDA in a moment. We ended the quarter with $907 million in cash, cash equivalents, and marketable securities, and are well capitalized to support commercial launches and development of our focused pipeline. Next slide, please. As I mentioned, we have the pieces in place to deliver on the commercial launch of midipivatin sickle cell disease. Let me take a moment to directly address a recent update on our SNDA. As we disclosed last week on October 9th, the FDA asked for additional information to evaluate whether a risk evaluation and mitigation strategy, or REMS, is necessary for midipivatin sickle cell disease. We responded within 10 days, including approximately nine months of additional safety data from the Rise Up Open Label Extension Period. The FDA classified our response as a major amendment, which procedurally extends the review timeline by three months to February 1, 2027. Let me be clear on why we remain confident in a potential approval in sickle cell disease. With this additional follow-up, there continues to be no cases of liver injury in sickle cell disease similar in pattern or severity to those seen in thalassemia. The benefit risk profile for Minipivet in sickle cell disease is unchanged. The FDA granted this application priority review, recognizing the serious unmet need, and that urgency has not changed. We are in ongoing labeling negotiations with the agency, including elements of a potential REBS, and we are launch ready. Our commercial medical market access and patient support teams are in place, and we continue to engage closely with the sickle cell community. Our focus is on bringing MediPivot to patients as quickly as possible. Next slide, please. Looking ahead, we are sharpening our focus to drive the next phase of growth. Our strategy is clear. First, maximize the MediPivot franchise. which is now approved in PK deficiency and thalassemia with sickle cell disease serving as another growth driver from early 2027. Second, advance a focused rare hematology pipeline. That includes AG236 and polycythemia vera where we plan to initiate a phase 2-3 program by year end and sevadoplinib in immune thrombocytopenia with a phase 3 trial planned for the first half of 2028. Importantly, both programs have clinically validated and de-risked mechanisms of action. To support that focus, we have right-sized our operating model. Over the course of 2026, we will have reduced R&D headcount by more than 35% compared with 2025, or more than 100 roles, and we expect associated cost savings to be realized in 2027. We are concentrating our clinical investment on differentiated rare hematology programs, and we are pursuing opportunities to unlock value from non-core assets, including our voracitinib royalty and EG181. As a result, we will continue to manage operating expenses as we prioritize investment behind our commercial launches and rare hematology pipeline opportunities and are targeting non-GAAP profitability in 2028. With that, please advance to the next slide and I'll turn the call over to Cecilia to discuss financials. Cecilia?
You're reading a preview of the AGIO Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing